Clinical Trials Directory

Trials / Terminated

TerminatedNCT03624517

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Medical University of South Carolina · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the safety and efficacy of 24-hour vs 72-hour octreotide infusion after variceal banding in cirrhotic patients with bleeding esophageal varices.

Detailed description

In cirrhotic patients with bleeding esophageal varices, standard of care therapy includes administration of octreotide infusion over 72-hours and endoscopic banding of esophageal varices. Octreotide acts to reduce the pressure in the blood vessels surrounding the liver, decreasing the propensity of bleeding from esophageal varices. The recommended duration of octreotide therapy is based largely on expert opinion, however a 72-hour duration of treatment is likely to be unnecessary and may inappropriately increase hospital and medical costs. This study aims to determine the safety of 24-hours of octreotide infusion in patients with bleeding esophageal varices.

Conditions

Interventions

TypeNameDescription
DRUGOctreotideOctreotide infusion for 24-hours in patients with bleeding esophageal varices.

Timeline

Start date
2018-09-19
Primary completion
2024-12-01
Completion
2024-12-01
First posted
2018-08-10
Last updated
2025-11-20
Results posted
2025-11-20

Locations

8 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03624517. Inclusion in this directory is not an endorsement.